Tyson L. Burden, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 445 E 10th St, Baxter Springs, KS 66713 Phone: 620-856-3469 Fax: 620-856-5330 |
News Archive
United Therapeutics Corporation announced today that the U.S. Food and Drug Administration (FDA) has issued an approval letter for the intravenous use of Remodulin based on data establishing its bioequivalence with the previously approved subcutaneous administration of Remodulin.
McKesson's Horizon Clinicals®, the industry's most comprehensive software suite used by clinicians, patients and healthcare executives to promote high quality, safe care, has received Complete EHR certification — deeming the software capable of enabling providers to meet the Stage 1 meaningful use measures required to qualify for funding under the American Recovery and Reinvestment Act (ARRA).
A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months in between treatments. This represents a vast improvement over the typical regimen of nearly monthly eye injections.
Gene therapy could be used as an agent to protect normal tissues, including the esophagus and lung, from damage during a second administration of radiation therapy for non-small cell lung cancer, according to an animal study presented by University of Pittsburgh researchers at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Denver.
› Verified 3 days ago